Terms: = Bone cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Treatment
13 results:
1. The Yin and Yang of erbb4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
2. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract] [Full Text] [Related]
3. her4 promotes the growth and metastasis of osteosarcoma via the PI3K/AKT pathway.
Li X; Huang Q; Wang S; Huang Z; Yu F; Lin J
Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):345-362. PubMed ID: 32181480
[TBL] [Abstract] [Full Text] [Related]
4. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.
Wang W; Zhao HF; Yao TF; Gong H
Invest New Drugs; 2019 Feb; 37(1):175-183. PubMed ID: 30353245
[TBL] [Abstract] [Full Text] [Related]
5. How does iliosacral bone tumor resection without reconstruction affect the ipsilateral hip joint?
Jin T; Liu W; Xu H; Li Y; Hao L; Niu X
BMC Musculoskelet Disord; 2018 Apr; 19(1):102. PubMed ID: 29615012
[TBL] [Abstract] [Full Text] [Related]
6. her4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1.
Wang H; Sun W; Sun M; Fu Z; Zhou C; Wang C; Zuo D; Zhou Z; Wang G; Zhang T; Xu J; Chen J; Wang Z; Yin F; Duan Z; Hornicek FJ; Cai Z; Hua Y
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1839-1849. PubMed ID: 29524631
[TBL] [Abstract] [Full Text] [Related]
7. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Dembla V; Groisberg R; Hess K; Fu S; Wheler J; Hong DS; Janku F; Zinner R; Piha-Paul SA; Ravi V; Benjamin RS; Patel S; Somaiah N; Herzog CE; Karp DD; Roszik J; Meric-Bernstam F; Subbiah V
Sci Rep; 2017 Nov; 7(1):15963. PubMed ID: 29162825
[TBL] [Abstract] [Full Text] [Related]
8. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma.
Jung IH; Yoon SM; Kwak J; Park JH; Song SY; Lee SW; Ahn SD; Choi EK; Kim JH
Oncotarget; 2017 Feb; 8(9):15182-15192. PubMed ID: 28146433
[TBL] [Abstract] [Full Text] [Related]
9. Mutational Profile of Metastatic Breast cancers: A Retrospective Analysis.
Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
[TBL] [Abstract] [Full Text] [Related]
10. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Scheipl S; Barnard M; Cottone L; Jorgensen M; Drewry DH; Zuercher WJ; Turlais F; Ye H; Leite AP; Smith JA; Leithner A; Möller P; Brüderlein S; Guppy N; Amary F; Tirabosco R; Strauss SJ; Pillay N; Flanagan AM
J Pathol; 2016 Jul; 239(3):320-34. PubMed ID: 27102572
[TBL] [Abstract] [Full Text] [Related]
11. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.
Tamborini E; Virdis E; Negri T; Orsenigo M; Brich S; Conca E; Gronchi A; Stacchiotti S; Manenti G; Casali PG; Pierotti MA; Pilotti S
Neuro Oncol; 2010 Aug; 12(8):776-89. PubMed ID: 20164240
[TBL] [Abstract] [Full Text] [Related]
12. The role of the EGFR signaling in tumor microenvironment.
De Luca A; Carotenuto A; Rachiglio A; Gallo M; Maiello MR; Aldinucci D; Pinto A; Normanno N
J Cell Physiol; 2008 Mar; 214(3):559-67. PubMed ID: 17894407
[TBL] [Abstract] [Full Text] [Related]
13. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents.
Rhee J; Oishi K; Garey J; Kim E
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S101-6. PubMed ID: 16336749
[TBL] [Abstract] [Full Text] [Related]